GlassScriptPhysician profile
Sasha O Joseph
NPI 1053576710
$1,187.20
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $166 · 2021: $114 · 2022: $476 · 2023: $42.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $325.74 | 2019-2022 | |
| Amgen INC. | $148.13 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $131.99 | 2020-2022 | |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.05 | 2019-2022 | |
| Celgene Corporation | $49.37 | 2022-2023 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $43.89 | 2019-2020 | |
| Astellas Pharma US INC | $36.66 | 2020-2022 | |
| Janssen Biotech, INC. | $23.25 | 2019 | |
| Abbvie INC. | $22.06 | 2022 | |
| Pfizer INC. | $21.31 | 2022 | |
| Sobi, INC | $20.76 | 2022 | |
| Beigene USA, INC. | $20.41 | 2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.31 | 2022 | |
| G1 Therapeutics, INC. | $19.35 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.71 | 2019 | |
| Lilly USA, LLC | $17.56 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.98 | 2019 | |
| Novocure INC. | $16.94 | 2022 | |
| Merck Sharp & Dohme LLC | $15.41 | 2019 | |
| Puma Biotechnology, INC. | $14.63 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.